GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (FRA:ET8) » Definitions » EV-to-EBIT

Cosciens Biopharma (FRA:ET8) EV-to-EBIT : 0.85 (As of Dec. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cosciens Biopharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cosciens Biopharma's Enterprise Value is €-8.93 Mil. Cosciens Biopharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €-10.51 Mil. Therefore, Cosciens Biopharma's EV-to-EBIT for today is 0.85.

The historical rank and industry rank for Cosciens Biopharma's EV-to-EBIT or its related term are showing as below:

FRA:ET8' s EV-to-EBIT Range Over the Past 10 Years
Min: -113.07   Med: 8.42   Max: 53.81
Current: 0.85

During the past 13 years, the highest EV-to-EBIT of Cosciens Biopharma was 53.81. The lowest was -113.07. And the median was 8.42.

FRA:ET8's EV-to-EBIT is ranked better than
67.53% of 425 companies
in the Biotechnology industry
Industry Median: 9.74 vs FRA:ET8: 0.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cosciens Biopharma's Enterprise Value for the quarter that ended in Sep. 2024 was €-6.51 Mil. Cosciens Biopharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €-10.51 Mil. Cosciens Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 161.38%.


Cosciens Biopharma EV-to-EBIT Historical Data

The historical data trend for Cosciens Biopharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma EV-to-EBIT Chart

Cosciens Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.80 23.93 12.19 5.91 -1.41

Cosciens Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.89 -1.41 -2.01 1.91 0.59

Competitive Comparison of Cosciens Biopharma's EV-to-EBIT

For the Biotechnology subindustry, Cosciens Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's EV-to-EBIT falls into.



Cosciens Biopharma EV-to-EBIT Calculation

Cosciens Biopharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-8.932/-10.506
=0.85

Cosciens Biopharma's current Enterprise Value is €-8.93 Mil.
Cosciens Biopharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosciens Biopharma  (FRA:ET8) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cosciens Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=-10.506/-6.5100294
=161.38 %

Cosciens Biopharma's Enterprise Value for the quarter that ended in Sep. 2024 was €-6.51 Mil.
Cosciens Biopharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosciens Biopharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.

Cosciens Biopharma Headlines

No Headlines